SEC Form 4 · accession 0001853529-26-000002

Edgewise Therapeutics, Inc. · EWTX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).

Reporting owner

Alan J Russell

Officer — Chief Scientific Officer · Director

Period of report

Aug 12, 2026

Accepted (ET)

Aug 14, 2026 · 4:53 pm EDT

Rule 10b5-1 plan

box not checked

Issuer CIK

0001710072

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock	Aug 12, 2026	M	5,781	$0.00	A	30,336	D
Common Stock	Aug 12, 2026	M	7,031	$0.00	A	37,367	D
Common Stock^F1,F2	Aug 12, 2026	S	3,238	$43.6775	D	34,129	D
Common Stock^F1,F3	Aug 12, 2026	S	2,273	$43.6759	D	31,856	D
Common Stock^F1	Aug 12, 2026	S	390	$44.46	D	31,466	D

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Restricted Stock Units^F4	$0.00	Aug 12, 2026	M	5,781	D	—	Aug 12, 2034	Common Stock	5,781	11,563	D
Restricted Stock Units^F5	$0.00	Aug 12, 2026	M	7,031	D	—	Aug 12, 2035	Common Stock	7,031	21,094	D
Restricted Stock Units^F6	$0.00	Aug 12, 2026	A	32,500	A	—	Aug 12, 2036	Common Stock	32,500	32,500	D
Stock Option (Right to Buy)^F7	$0.00	Aug 12, 2026	A	65,000	A	—	Aug 12, 2036	Common Stock	65,000	65,000	D

Explanation of responses

F1Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person.
F2The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $43.33 to $44.26, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $43.32 to $44.25, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2025.
F5Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2026.
F6Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2027.
F71/48th of the shares subject to the option vest each month beginning on September 12, 2026, subject to the Reporting Person continuing as a service provider through each vest date.